{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:38:54Z","timestamp":1787009934848,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"16","license":[{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Innovative coronavirus disease 2019 (COVID-19) vaccines, with elevated global manufacturing capacity, enhanced safety and efficacy, simplified dosing regimens, and distribution that is less cold chain-dependent, are still global imperatives for tackling the ongoing pandemic. A previous phase I trial indicated that the recombinant COVID-19 vaccine (V-01), which contains a fusion protein (IFN-PADRE-RBD-Fc dimer) as its antigen, is safe and well tolerated, capable of inducing rapid and robust immune responses, and warranted further testing in additional clinical trials. Herein, we aimed to assess the immunogenicity and safety of V-01, providing rationales of appropriate dose regimen for further efficacy study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A randomized, double-blind, placebo-controlled phase II clinical trial was initiated at the Gaozhou Municipal Centre for Disease Control and Prevention (Guangdong, China) in March 2021. Both younger (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u200a=\u200a440; 18\u201359 years of age) and older (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u200a=\u200a440; \u226560 years of age) adult participants in this trial were sequentially recruited into two distinct groups: two-dose regimen group in which participants were randomized either to follow a 10 or 25 \u03bcg of V-01 or placebo given intramuscularly 21 days apart (allocation ratio, 3:3:1,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u200a=\u200a120, 120, 40 for each regimen, respectively), or one-dose regimen groups in which participants were randomized either to receive a single injection of 50 \u03bcg of V-01 or placebo (allocation ratio, 3:1,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u200a=\u200a120, 40, respectively). The primary immunogenicity endpoints were the geometric mean titers of neutralizing antibodies against live severe acute respiratory syndrome coronavirus 2, and specific binding antibodies to the receptor binding domain (RBD). The primary safety endpoint evaluation was the frequencies and percentages of overall adverse events (AEs) within 30 days after full immunization.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      V-01 provoked substantial immune responses in the two-dose group, achieving encouragingly high titers of neutralizing antibody and anti-RBD immunoglobulin, which peaked at day 35 (161.9 [95% confidence interval [CI]: 133.3\u2013196.7] and 149.3 [95%CI: 123.9\u2013179.9] in 10 and 25 \u03bcg V-01 group of younger adults, respectively; 111.6 [95%CI: 89.6\u2013139.1] and 111.1 [95%CI: 89.2\u2013138.4] in 10 and 25 \u03bcg V-01 group of older adults, respectively), and remained high at day 49 after a day-21 second dose; these levels significantly exceed those in convalescent serum from symptomatic COVID-19 patients (53.6, 95%CI: 31.3\u201391.7). Our preliminary data show that V-01 is safe and well tolerated, with reactogenicity predominantly being absent or mild in severity and only one vaccine-related grade 3 or worse AE being observed within 30 days. The older adult participants demonstrated a more favorable safety profile compared with those in the younger adult group: with AEs percentages of 19.2%, 25.8%, 17.5% in older adults\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      34.2%, 23.3%, 26.7% in younger adults at the 10, 25 \u03bcg V-01 two-dose group, and 50 \u03bcg V-01 one-dose group, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The vaccine candidate V-01 appears to be safe and immunogenic. The preliminary findings support the advancement of the two-dose, 10\u200a\u03bcg V-01 regimen to a phase III trial for a large-scale population-based evaluation of safety and efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration:<\/jats:title>\n                    <jats:p>http:\/\/www.chictr.org.cn\/index.aspx (No. ChiCTR2100045107, http:\/\/www.chictr.org.cn\/showproj.aspx?proj=124702).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000001702","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T23:02:47Z","timestamp":1626390167000},"page":"1967-1976","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":32,"title":["Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial"],"prefix":"10.1097","volume":"134","author":[{"given":"Ya-Jun","family":"Shu","sequence":"first","affiliation":[{"name":"Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, Guangdong 510440, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Feng","family":"He","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong 511430, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Juan","family":"Pei","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei 430071, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"He","sequence":"additional","affiliation":[{"name":"National Institutes for Food and Drug Control, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu-Hang","family":"Huang","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, Guangdong 510440, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Min","family":"Chen","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, Guangdong 510440, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Qiang","family":"Ou","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, Guangdong 510440, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Long","family":"Deng","sequence":"additional","affiliation":[{"name":"Gaozhou Center for Disease Control and Prevention, Maoming, Guangdong 525000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Yu","family":"Zeng","sequence":"additional","affiliation":[{"name":"Gaozhou Center for Disease Control and Prevention, Maoming, Guangdong 525000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[{"name":"Gaozhou Center for Disease Control and Prevention, Maoming, Guangdong 525000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Qin","family":"Min","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei 430071, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Deng","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei 430071, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Peng","sequence":"additional","affiliation":[{"name":"Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Shenzhen, Guangdong 518112, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wang","sequence":"additional","affiliation":[{"name":"Livzon Bio Inc., Zhuhai, Guangdong 519045, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Hui","family":"Xu","sequence":"additional","affiliation":[{"name":"Livzon Bio Inc., Zhuhai, Guangdong 519045, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu-Xiang","family":"Guan","sequence":"additional","affiliation":[{"name":"Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei 430071, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Yu","family":"Hu","sequence":"additional","affiliation":[{"name":"National Institutes for Food and Drug Control, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Kai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, Guangdong 510440, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/S0140-6736(20)32153-X","article-title":"Scientific consensus on the COVID-19 pandemic: we need to act now","volume":"396","author":"Alwan","year":"2020","journal-title":"Lancet"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/s41591-021-01318-5","article-title":"Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies","volume":"27","author":"Planas","year":"2021","journal-title":"Nat Med"},{"key":"R4-20250603","article-title":"Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees","author":"Yadav","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R5-20250603","article-title":"Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals","author":"Planas","year":"2021","journal-title":"bioRxiv"},{"key":"R6-20250603","article-title":"Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees","author":"Yadav","year":"2021","journal-title":"bioRxiv"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1056\/NEJMoa2105000","article-title":"Vaccine breakthrough infections with SARS-CoV-2 variants","volume":"384","author":"Hacisuleyman","year":"2021","journal-title":"N Engl J Med"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N Engl J Med"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0140-6736(21)00241-5","article-title":"Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial","volume":"397","author":"Richmond","year":"2021","journal-title":"Lancet"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"R11-20250603","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(21)00127-4","article-title":"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials","author":"Yang","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1056\/NEJMc2101667","article-title":"Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine","volume":"384","author":"Krammer","year":"2021","journal-title":"N Engl J Med"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"111254","DOI":"10.1016\/j.biopha.2021.111254","article-title":"Targets and strategies for vaccine development against SARS-CoV-2","volume":"137","author":"Malik","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"R14-20250603","article-title":"Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2","author":"Sun","year":"2021","journal-title":"bioRxiv"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.4049\/jimmunol.161.4.1947","article-title":"Type I IFNs enhance the terminal differentiation of dendritic cells","volume":"161","author":"Luft","year":"1998","journal-title":"J Immunol"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1074-7613(94)80017-0","article-title":"Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides","volume":"1","author":"Alexander","year":"1994","journal-title":"Immunity"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"e66134","DOI":"10.1371\/journal.pone.0066134","article-title":"IFN-alpha as an adjuvant for adenovirus-vectored FMDV subunit vaccine through improving the generation of T follicular helper cells","volume":"8","author":"Su","year":"2013","journal-title":"PLoS One"},{"key":"R18-20250603","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","author":"Khoury","year":"2021","journal-title":"Nat Med"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000001702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T16:22:54Z","timestamp":1748967774000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000001702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,22]]},"references-count":18,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000001702","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,22]]}}}